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1. INTRODUCTION 
1.1 Terms of Reference of the Review Group 
The Review Group was set up to consider the arrangements in place for the management 
and care of heroin dependent drug misusers by general practitioners and pharmacists and 
to advise the Minister on the approach to be taken in the future. The group was first 
convened on 13th January 1997 and its terms of reference were:- 
(a) to examine and define the role of general practitioners and pharmacists in the 
treatment of opiate dependent persons, 
(b) to examine the working relationships between the various treatment centres and 
general practitioners and pharmacists, and 
(c) to outline protocols for good practice in the prescribing and dispensing of 
methadone, including appropriate controls which might be put in place. 
1.2 Membership of the Review Group 
Membership of the Review Group reflected the various agencies which have a role to 
play in the provision of services for drug misusers. These were the Department of Health, 
the Eastern Health Board, the Irish College of General Practitioners and the 
Pharmaceutical Society of Ireland. 
Mr Jimmy Duggan, Principal Officer, Community Health Division (Chairman) 
Dr Jim Kiely, Chief Medical Officer, Department of Health 
Mr Tom McGuinn, Chief Pharmacist, Department of Health 
Ms Noreen Quinn, Pharmacist, Department of Health 
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Dr Joe Barry, Public Health Specialist, Eastern Health Board 
Dr Brion Sweeney, Consultant Psychiatrist, Eastern Health Board (representing the 
Consultants working in substance misuse in the Eastern Health Board) 
Dr Ide Delargy, Irish College of General Practitioners 
Ms Sile O’ Connor, Pharmaceutical Society of Ireland 
(Ms Eugenic Canauan or Ms Leonie Clarke attended meetings when 
Ms O’Connor was unavailable). 
Ms Mary Jackson, Assistant Principal, Community Health Division 
Mr Joe Gavin, Higher Executive Officer, Community Health Division, acted as 
Secretary to the Group. 
The Group met on 13 occasions, which included meetings with representatives from the 
Merchants Quay Project, Professor Gerard Bury, Department of General Practice, UCD, 
and the Irish Pharmaceutical Union. 
1.3 Protocol for the Prescribing of Methadone 
1.3.1 The Report of the Expert Group on a Protocol for the Prescribing of Methadone, 
which was published in March, 1993, set out recommendations in the form of a Protocol 
for the involvement of general practitioners and community pharmacists in methadone 
maintenance programmes (Appendix 1). 
This Protocol recommended that general practitioners should become involved by taking 
on responsibility for the care of opiate dependent persons who had first been stabilised at 
community drug treatment centres. It also outlined the criteria necessary to ensure that 
methadone prescribing occurred in a controlled, responsible fashion. Many elements of 
the Protocol have been implemented. Most notably, a central 
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treatment list of patients being prescribed methadone has been established on a voluntary 
basis. Under this arrangement a general practitioner who is considering prescribing 
methadone for a patient can check whether the patient’s name is on this treatment list and 
so minimise the possibility that the patient concerned is receiving methadone from more 
than one source. 
1.3.2 In March 1996 a methadone maintenance pilot project, involving general 
practitioners and pharmacists in the Eastern Health Board region, commenced. It 
involved the selection of a number of patients who had been stabilised in drug treatment 
centres and who were referred to general practitioners in their own local area for 
continuation of methadone treatment and overall medical care. 
This pilot programme included the key elements of the Protocol which were:- 
* the provision of a personalised treatment card to each patient - this card was in turn 
presented to a local pharmacist who held it for the duration of treatment; 
* support to GPs and pharmacists through the appointment of a GP facilitator; 
* close liaison and communication arrangements with health board services in the 
event of a patient destabilising ; 
* contractual arrangements with GPs, pharmacists etc. 
1.3.3 Professor Gerard Bury, under the auspices of the Department of General Practice in 
University College Dublin, carried out an independent evaluation of the pilot protocol 
programme. This evaluation involved a comparison of general practice care and treatment 
centre care of stable patients over a period of at least six months. While the final results 
of the study are not yet available, an initial analysis suggests 
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very similar outcomes for both groups of patients. Feedback from patients and general 
practitioners involved in the study has also been very positive. 
1.3.4 A number of other schemes have developed in parallel with the pilot programme 
and almost 600 people have been issued with treatment cards to date. Seventy three 
general practitioners are involved in prescribing and 62 pharmacies are participating in 
the controlled dispensing of methadone mixture DTF Img/ml- 
1.4 Ministerial Task Force Report 
In order to address the serious problems relating to drug misuse, particularly in the 
Eastern Health Board area, a Ministerial Task Force on Measures to Reduce the Demand 
for Drugs was established in 1996. In its first report, published in October, 1996, the Task 
Force recommended, inter alia, that the GP/Pharmacist methadone 
prescription/dispensing scheme should continue to be expanded, evaluated and strictly 
regulated- 
1.5 Pharmaceutical Society of Ireland’s Policy on Drug Abuse 
In its policy document on drug misuse, which was published in October, 1996, the 
Pharmaceutical Society of Ireland acknowledged the valuable role played by methadone 
treatment in the management of opiate addiction. It encouraged pharmacists to participate 
in methadone dispensing in accordance with specific guidelines (which were in 
agreement with the recommendations in the Protocol and with Department of Health 
policy). The document also highlighted important points from a pharmacist’s perspective, 
which would make it more attractive to pharmacists to become involved in methadone 
dispensing. A copy of the executive summary of this document is attached at Appendix 2. 
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1.6 Irish College of General Practitioners’ Task Group’s Report on Drug Misuse 
The Irish College of General Practitioners published a Report of the Task Group on Drug 
Misuse in May, 1997. This report recommends that general practitioners should become 
involved in the treatment of opiate misusers in their own. local communities, which is in 
accordance with joint guidelines of the Medical Council. It also recommended that 
methadone treatment as described in the Protocol should continue as a valid form of 
treatment for opiate dependence. The executive summary of this document is attached at 
Appendix 3. 
1.7 Eastern Health Board Policy 
The Eastern Health Board is engaged in a major expansion of its services for drug 
misusers with the aim of eliminating waiting lists for drug treatment by the end of 1997, 
As part of this programme methadone treatment would be provided to opiate misusers 
either in drug treatment centres or through arrangements being made with their local 
general practitioner and pharmacist. The Board has recommended that stricter regulation 
and control of methadone should be applied in the course of this expansion. In particular, 
it has recommended that it should be compulsory for doctors to notify the central 
treatment list of all patients for whom they are prescribing methadone. Further 
examination of this issue is required. 
2. EXTENT OF METHADONE USAGE 
A central treatment list for the prescribing of methadone was set up in 1993. Since that 
date a total of about 4,300 persons have been on methadone treatment. On 13th June 
1997 there were 2,232 persons on the central methadone treatment list. Of this group 
approximately half were receiving treatment in an Eastern Health Board treatment centre, 
or in the Drug Treatment Centre, Pearse Street. The remainder were being treated by 
general practitioners. 
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3. GENERAL CONCLUSIONS OF THE GROUP 
Having reviewed the issues involved in treatment of opiate dependent persons in their 
own local communities the Group has come to the following conclusions;- 
(a) methadone treatment continues to be a valid treatment for opiate dependent 
persons, but it must be part of a comprehensive programme of care; 
(b) the Protocol for the Prescribing of Methadone, as set out in March, 1993 in the 
Expert Group report, should be the basis on which the further development of 
services for opiate dependent persons is undertaken, subject to appropriate 
controls; 
(c) methadone mixture DTF Img/ml should be the only strength of methadone used 
for the treatment of opiate dependence, because of less scope for confusion and 
accidental overdose and also because it is more appropriate for the treatment of 
opiate dependence-Methadone linctus 2mg/5ml should be discontinued, except on 
a “named-patient” basis; 
(d) the sugar-free formulation of methadone mixture DTF Img/ml should be used, 
except in exceptional circumstances. Bottles should be fitted with child-proof caps; 
(e) methadone should be available free of charge to all persons undergoing methadone 
treatment for opiate dependence; 
(f) the methadone treatment protocol scheme should be available nationally; 
(g) there is a need to strictly control the prescribing and supply of methadone and a 
system of close monitoring of the prescribing and dispensing of methadone should 
be put in place immediately. A special group should be established for this purpose; 
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(h) regulations should be introduced to require that the prescription and supply of 
methadone should be restricted to official prescription forms, specifically designed 
for the purpose; 
(i) methadone linctus 2mg/5ml should cease to be used for the treatment of opiate 
dependence and manufacturers concerned should be requested to cease the 
marketing of this product with effect from an agreed date, after which it would 
only be made available on a “named-patient” basis, in appropriate circumstances. 
4. RECOMMENDATIONS ON THE ROLE OF GENERAL PRACTITIONERS 
4.1 Involvement of General Practitioners 
The involvement of general practitioners in prescribing methadone to opiate dependent 
persons who live in their local area is vital to the overall success of health board drug 
treatment programmes. The Group examined present practice among GPs, taking into 
account advice which it had received through the recommendations in the Irish College 
of General Practitioners’ Report of the Task Group on Drug Misuse. Issues which were 
examined included contracting of GPs by the Health Board and support from local health 
board services for GPs. 
4.2 The GP Contract 
The Review Group decided to endorse and adopt the scheme of general practitioner 
involvement outlined in the Irish College of General Practitioners’ Report. Under this 
scheme general practitioners should be contracted by the Health Board to provide 
treatment on the basis of one of the two levels outlined below. 
4.2.1 Level 1 Contract: This level would relate to doctors treating stabilised opiate 
dependent persons referred from health board drug treatment centres. The contract would 
include the following elements:- 
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* the general practitioner should have adequate training in the knowledge, skills and 
attitudes required to manage opiate misusers in general practice. This would 
require completion of a recognised training programme agreed between the Irish 
College of General Practitioners and the Eastern Health Board; 
* the general practitioner should ensure that any opiate dependent person he/she is 
treating is registered on the Central Treatment List (currently held at the Drug 
Treatment Centre, Pearse Street); 
* the general practitioner should satisfy him/herself as to the identity of any opiate 
dependent person he/she is treating- He/She should also ensure that the person has 
a treatment card with a recent photograph, name, signature and date of birth, the 
correct pharmacist’s name and address and that this treatment card is not out of 
date. He/She should also make contact with the pharmacist at an early stage in 
order to make appropriate arrangements regarding dispensing- This contact should 
continue during the course of treatment; 
* the general practitioner should agree to provide services to a maximum of 15 
patients; 
* the general practitioner should agree to liaise with a “keyworker”, as set out in the 
Protocol, for each patient; 
* the general practitioner should agree to a regular audit/evaluation of his/her 
practice by an Irish College of General Practioners/Eastern Health Board team; 
* the general practitioner should agree to regular educational updates as arranged by 
the Irish College of General Practitioners / Eastern Health Board team; 
* treatment should be provided in local areas as recommended by the Medical 
Council of Ireland and the Pharmaceutical Society of Ireland, 
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* the general practitioner should agree that no fees will be accepted from a patient, 
or any source other than the Health Board, for providing this service; 
* prescriptions for methadone should not enable supply for a period greater than 
seven days, in the course of a single dispensing. Other arrangements may be 
necessary in exceptional circumstances. In all cases the general practitioner must 
be satisfied that it is safe to issue the prescription concerned; 
4.2.2 Level 2 Contract would involve general practitioners who had more training and 
experience of working with opiate dependent persons. These general practitioners could 
initiate treatment of opiate dependent persons. 
The terms of the Level 2 Contract would include all of the Level 1 terms and in addition:- 
* the general practitioner should have undergone a more advanced training 
programme as agreed between the Irish College of General Practitioners and the 
Eastern Health Board (including supervision by an experienced general 
practitioner for 1 year in a treatment centre setting); 
* the general practitioner should agree to an annual refresher course and regular 
evaluation of the practice; 
* the general practitioner should treat up to a maximum of 35 patients in his or her 
own practice; 
* general practitioners in a practice with 2 or more doctors could cater for a 
maximum of 50 patients; 
* in certain exceptional circumstances general practitioners may, following 
consultation with the health board’s consultant psychiatrists, be approved to treat a 
greater number of patients. 
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This may be necessary, particularly in the short term where there is still a difficulty 
in recruiting new general practitioners to become involved in treatment; 
It is intended that only general practitioners who conform to the criteria set out above 
should treat opiate dependent persons. 
5. RECOMMENDATIONS ON THE ROLE OF PHARMACISTS 
5.1 Involvement of Community Pharmacists 
The involvement of community pharmacists in the dispensing of methadone allows for a 
large number of opiate dependent persons to be successfully treated in their own local 
area. Health Boards will enter into a contract with pharmacists to dispense (including the 
supervised administration of) methadone mixture DTF Img/ml to opiate dependent 
persons in their local area, on special methadone protocol prescription forms, in 
accordance with the terms set out below. 
5.2 Pharmacist’s Contract 
* Methadone mixture DTF Img/ml should only be dispensed on receipt of a correctly 
written prescription, written on a special prescription form, which would allow for 
a single supply or supply on installment. The prescription should also indicate 
whether the administration of the dose should be supervised by the pharmacist or 
not. 
* Methadone should only be dispensed to patients who hold a valid treatment card. 
Each patient should have a treatment card which would show their name, address, 
signature and date of birth and contain a recent photograph. This card should also 
indicate the name and address of the prescribing GP and have an expiry date. 
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The card should be delivered in advance to the pharmacist who should be briefed 
on how the system works by the GP co-ordinator or the liaison pharmacist. 
* The treatment card should be lodged with the pharmacist for the duration of 
treatment or until it expired or was replaced, or withdrawn. 
* Provision should be made for a patient to be referred back to the health board 
treatment services if the patient fails to comply with an agreed code of behaviour. 
* Ideally there should be an upper limit of 50 clients attending any single pharmacy. 
Provision could, however, be made for numbers in excess of this in certain 
circumstances, where, for example, it proved impossible to recruit a sufficient 
number of pharmacists in a locality. The overriding principle should, nevertheless, 
continue to be that community pharmacists, wherever possible, dispense 
methadone to patients from their immediate locality. 
5.3 Training for Pharmacists 
It is essential that pharmacists who wish to become involved in methadone dispensing 
obtain the relevant training and information in order to assist them in carrying out their 
role successfully. It is also important that pharmacists get regular updates on drug misuse 
and specifically on methadone treatment, in order that they keep well informed about 
current issues. For these reasons it is recommended that training sessions are organised 
both for pharmacists wishing to become involved in dispensing of methadone and for 
those already dispensing to opiate misusers. 
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6. WORKING RELATIONSHIPS BETWEEN TREATMENT CENTRES AND 
GENERAL PRACTITIONERS AND PHARMACISTS 
6.1 Transfer of Patients to General Practice 
6.1.1 At present when a patient is transferring to general practice from a health board 
treatment centre, the Health Board’s GP co-ordinator contacts the GP and informs 
him/her of the details relating to that person. The Health Board provides a designated key 
worker for each patient and where it is deemed necessary and if the patient so wishes, 
they will also have access to a community addiction counsellor. Facilities for supervised 
urines are arranged. The GP enters into a contract with the Board to provide methadone 
treatment, strictly in accordance with the Protocol. A special prescription form, which is 
issued by the General Medical Services (Payments) Board, is supplied to the GP. 
6.1.2 Contact is made with a local pharmacist who agrees to dispense methadone mixture 
DTF Img/ml strictly in accordance with the Protocol and a contract is entered into 
between the Health Board and the pharmacist. The opiate dependent person is provided 
with a treatment card and is registered on the central methadone treatment list. At the 
same time the Department of Health is notified of the new patient and of the pharmacist 
involved so that arrangements can be made for the supply of methadone mixture DTF 
Img/ml to that pharmacy. The Department of Health then:- 
* notifies, if necessary, the pharmacist’s wholesaler that methadone mixture DTF 
Img/ml may be supplied to the pharmacist for a patient; 
* notifies the General Medical Services (Payments) Board about the pharmacist’s 
involvement, so that arrangements can be made for payment to the pharmacist for 
methadone by the Board on receipt of appropriate claim forms; 
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* writes to the pharmacist stating that methadone mixture DTF 1 mg/ml should only 
be dispensed to the patient or patients named in that letter and asking the 
pharmacist to confirm his/her agreement to this process. 
6.1.3 The pharmacist replies to the Department, agreeing to the terms of the protocol. The 
patient presents the treatment card to the pharmacist and on receipt of a correctly written 
prescription form from that patient, methadone is dispensed. If, for any reason, the patient 
destabilises or problems are created, the pharmacist contacts the Health Board co-
ordinator in order to make arrangements for the patient’s return to health board services. 
These arrangements were put in place to ensure that strict controls applied to the 
operation of the scheme. It is recommended that these should continue under the aegis of 
the Eastern Health Board. 
6.2 Future Plans for Co-ordination of Methadone Schemes. 
The Eastern Health Board and the Drug Treatment Centre in Pearse Street will provide 
on-going support to GPs and pharmacists involved in methadone treatment as follows:- 
(a) the Eastern Health Board has been divided into 3 sectors for the purpose of 
co-ordinating drug misuse services. Within each sector the Consultant 
Psychiatrists, Area Operations Managers and GP Co-ordinators, together 
with two Liaison Pharmacists, will ensure effective management of services; 
(b) patients will be provided with support from health board counselling and 
outreach staff. The Board is in the process of employing additional 
counsellors and support workers for this purpose. Voluntary agencies 
working in the locality of drug users will also be supported to provide this 
service. The Board has also installed a telephone helpline service, 
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operating from 10.00 a.m. to 5.00 p.m., Monday to Friday, which can deal 
with crisis calls from drug misusers or family members and direct them to 
the appropriate services; 
(c) information will be prepared for pharmacists which will include guidelines 
on the handling of methadone and on supervised consumption; 
(d) information will also be provided to GPs which will include guidance on 
upper limits of dosage, urine screening, maximum number of patients; 
(e) The Health Board will provide GPs with an audit form, which will be 
completed on an annual basis in conjunction with the GP co-ordinator and 
the Eastern Health Board’s Consultant Psychiatrists in accordance with the 
recommendations of the Irish College of General Practitioners/Eastern 
Health Board team; 
(f) a comprehensive treatment plan will be put in place in respect of each 
patient. This will include medical, social and psychological care. A regular 
review will also be made of each patient’s progress on methadone treatment. 
7. PLAN FOR INTRODUCTION OF THE SCHEME 
7.1 Wider Implementation of the Methadone Protocol 
7.1.1 The Group recommends that all patients under treatment for opiate misuse should 
be transferred to the methadone mixture DTP Img/ml product as soon as possible, in strict 
accordance with the Protocol. 
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7.1.2 Every general practitioner and pharmacist will be informed of the philosophy 
behind the new system and of the procedures to be undertaken. All general practitioners 
and pharmacists will receive a copy of the Protocol for the Prescribing of methadone and 
details of the arrangements, including the contact persons and their telephone numbers in 
case of emergency. As and from a specified date methadone mixture DTF Img/ml only 
will be available and all supplies of DTF will be restricted to patients who have valid 
treatment cards. It is anticipated that there would be a “lead in” time of some months to 
accomplish the issuing of treatment cards and auditing of GPs who wish to become 
involved. 
7.1.3 Training seminars for both GPs and pharmacists will be arranged by the Eastern 
Health Board on a regular basis, commencing immediately. 
8. SCHEME OF MONITORING AND CONTROL OF 
METHADONE USAGE 
8.1 Statutory Basis for Scheme of Monitoring 
It is recommended that a scheme of monitoring of methadone usage be introduced and 
that it should be placed on a statutory basis by Regulations under Section 5 of the Misuse 
of Drugs Act, 1977. The Review Group agreed that the following should form the basic 
elements of a scheme designed to monitor the prescribing and use of medicinal products 
containing methadone, its salts and preparations. 
(a) prohibition of the writing of prescriptions for methadone except on a 
prescribed prescription form supplied by, or on behalf of the Minister (i.e. 
the prescribed form); 
(b) prohibition of the dispensing of any prescription for methadone unless it has 
been written on the prescribed form; 
 
 
19 
(c) the prescribed prescription form should be available on a multiform basis. 
One copy would be supplied to a single national centre for review and 
monitoring. While a separate form may be made available for use in 
installment dispensing, consideration will be given to the incorporation of 
single dispensing and installment dispensing facilities within the one 
prescription form; 
(d) any pharmacist who dispenses a prescription for methadone would be 
required to forward a copy of that prescription to the designated national 
centre (probably at the end of each month) for the purpose of review and 
monitoring; 
(e) in order to assist in the measurement of the extent of opiate misuse doctors 
would be required to complete a Health Research Board report form once a 
year in respect of each person for whom they had prescribed methadone. 
9. OTHER RECOMMENDATIONS FOR THE EXTENDED 
IMPLEMENTATION OF THE METHADONE PROTOCOL 
The group has also made the following recommendations:- 
(a) all staff involved in the treatment of opiate misusers should be immunised 
against Hepatitis B. This would include pharmacists and their staff; 
(b) a leaflet should be prepared for patients attending pharmacies. This leaflet 
should outline the main issues involved in the introduction of the new 
scheme i.e. methadone mixture DTF 1 mg/ml, free of charge, treatment card, 
expiry date, review of treatment cards, etc; 
(c) GPs should be issued with a conversion chart from methadone linctus 
2mg/5ml to methadone mixture DTF Img/ml. 
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10 SUMMARY OF MAIN RECOMMENDATIONS OF THE 
METHADONE TREATMENT SERVICES REVIEW GROUP. 
1. Methadone treatment should continue to be a valid treatment for opiate 
dependence, as part of a comprehensive programme of care. [3.(a)] 
2. The Protocol for the Prescribing of Methadone as set out in March, 1993 should be 
the basis on which the further development of services for opiate dependent 
persons is undertaken, subject to appropriate controls. [3.(b)] 
3. There should be only one form of methadone used for the treatment of opiate 
dependence - methadone mixture DTF Img/ml. Methadone linctus 2mg/5ml should 
be discontinued, except on a “named-patient” basis. [3.(c) and (i)] 
4. The sugar-free formulation of methadone mixture DTF Img/ml should be used, 
except in exceptional circumstances and bottles should be fitted with child-proof 
caps. [3.(d)] 
5. Methadone should be available free of charge to all persons undergoing methadone 
treatment for opiate dependence. [3.(e)] 
6. The methadone treatment protocol should be available nationally. [3.(f)] 
7. The prescription and supply of methadone should be strictly controlled and a 
system of close monitoring of all elements of this scheme should be put in place 
immediately- A special group should be established for this purpose. [3-(g)] 
8. Regulations should be introduced to require that the prescription and supply of 
methadone should be restricted to official prescription forms specifically designed 
for the purpose. [3.(h)] 
9. Treatment for opiate misuse should be provided in the misuser’s 
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own local area wherever possible, as recommended by the Pharmaceutical Society 
of Ireland, the Medical Council and the Irish College of General Practitioners- [1.5 
and 1.6] 
10. General practitioners should provide methadone treatment to opiate misusers who 
reside in their local area, in accordance with the terms of the proposed GP 
Contract, as set out in this document and as endorsed by the Irish College of 
General Practitioners. [4.2] 
11. Pharmacists should dispense methadone to opiate misusers who reside in their 
local area, in accordance with the terms of the proposed Pharmacist’s Contract, as 
set out in this document. [5.2] 
12. The Eastern Health Board (and other health boards where necessary) should ensure 
that proper structures for effective working relationships between treatment centres 
and general practitioners and pharmacists are put in place. [6.2] 
13. All patients under treatment for opiate misuse should be transferred to the 
Methadone mixture DTF 1 mg/ml as soon as possible, in strict accordance with the 
Protocol- [7.1.1] 
14. GPs and pharmacists should be informed immediately about the philosophy behind 
the scheme and they should also receive a copy of this report. [7.1.2] 
15. GPs and pharmacists should be provided with specific training and information on 
the treatment of opiate dependent persons. [4.2. 5.3 and [7.1.3] 
16. The methadone monitoring scheme should be placed on a statutory basis by the 
making of Regulations under Section 5 of the Misuse of Drugs Act, 1977. [8-1] 
17. All staff involved in the treatment of opiate misusers should be immunised against 
Hepatitis B. This would include pharmacists and their staff. [9.(a)] 
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18. A leaflet should be prepared for patients attending pharmacies. This leaflet should 
outline the main issues involved in the introduction of the new scheme i.e. 
methadone mixture DTP Img/ml, free of charge, treatment card, expiry date, etc. 
[9.(b)] 
19. GPs should be issued with a conversion chart from methadone linctus 2mg/5ml to 
methadone mixture DTF Img/mi. [9-(c)] 
In the course of this review it was noted that it may be necessary at a future date to 
introduce monitoring of other drugs used in the treatment of drug misuse in a similar 
fashion. However, the Group felt that the controls and regulations which will be 
introduced regarding methadone and the training and education programmes which will 
be delivered to both general practitioners and pharmacists will, in turn, lead to a general 
improvement in the system. 
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APPENDIX 1 
REPORT OF THE EXPERT GROUP ON THE 
ESTABLISHMENT OF A PROTOCOL FOR THE 
PRESCRIBING OF METHADONE 
26 March 1993 
1. INTRODUCTION 
1.1 Of the 315 cases of AIDS reported in this country, (to 25 February, 1993), 144 
were drug use related; 1,381 persons had tested positive for the HIV antibody in the same 
period and almost 50% of these cases were drug use related. It is therefore apparent that 
injecting drug use is extremely high risk behaviour and an important source of 
transmission of the HIV virus in this country. Methadone therapy together with 
counselling and needle exchange are recognised strategies in preventing the spread of the 
HIV virus. 
However, the use of methadone presents problems for patients, pharmacists, doctors and 
health workers. This Group has addressed these difficulties in order to develop a practical 
protocol that will ensure maximum benefit for the patient while at the same time 
protecting the pharmacists, doctors and health workers involved in methadone therapy in 
the community. 
1.2 The National AIDS Strategy Committee has accepted the recommendations of the 
four Sub-Committees which it had previously established to examine various aspects of 
its brief. The Strategy Committee endorsed the recommendation that it would be 
necessary to allow methadone prescribing in the proposed satellite clinics in order to 
ensure that drug users availed of the full range of treatment services. It was also accepted 
that agreed protocols for the treatment of drug-using individuals needed to be established 
in order to avoid unnecessary pressure being placed on the general practitioner to 
prescribe opiates 
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and other drugs. It was envisaged that this would also lead to the avoidance of double 
prescribing and inappropriate prescribing- The National AIDS Strategy Committee 
considered that the appropriate agencies to prepare such protocols were the Drug 
Treatment Centre, the Eastern Health Board, the Irish College of General Practitioners 
and voluntary drug agencies. 
1.3 Accordingly, the Minister for Health established an Expert Group with the 
following membership to develop the protocol: - 
Dr J. H. Walsh, Department of Health (Chairman) 
Dr. J. Barry, Drugs - HIV/AIDS Co-Ordinator, 
Eastern Health Board 
Mr. T. Geoghegan, Project Leader, Merchant’s Quay Project 
Dr. J. O’ Connor, Clinical Director, Drug Treatment Centre 
Dr. F. O’ Kelly, Irish College of General Practitioners 
Dr. B. Sweeney, Consultant Psychiatrist, Eastern Health Board, 
Psychiatric Services. 
Mr. D. Ryan, Department of Health, was appointed Secretary to the Group. 
1.4 The Group was asked to consider the following in particular: 
− Methadone prescribing 
− Registration of drugs users and 
− Licensing of general practitioners to treat drug users. 
1.5 The Group gratefully acknowledges the submissions received from 
individuals and organisations which greatly assisted the Group in the preparation of this 
Report. In particular the supportive and co-operative assistance offered by the 
Pharmaceutical Society of Ireland and the Irish 
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Pharmaceutical Union was essential to the preparation of this Report. The Group is also 
most appreciative of the work and support of the Irish College of General Practitioners in 
the areas of illicit drug use and drug addiction. 
1.6 The Group wishes to record its acknowledgement of the valuable contributions to 
the work of the Group made by Ms. S. Stafford-Johnson, Senior Clinical Psychologist 
and Dr. E. Keenan, Senior Registrar, both of the Drug Treatment Centre. 
2. COMMUNITY BASED TREATMENT OF DRUG USERS 
2.1 Methadone prescribing 
The National AIDS Strategy Committee accepted that the prescribing of methadone was 
necessary to ensure that drug users would be encouraged to avail of the full spectrum of 
preventative measures and treatment services. This is particularly significant in view of 
the preponderance of HIV/AIDS in the drug-using community resulting in the spread of 
the infection as a result of sharing of contaminated needles. The Group discussed its remit 
at some considerable length and finally agreed on the following basic tenets:- 
1. That maintenance programmes represented, for many users, their most feasible 
option for stabilising their addiction. These programmes had obvious attractions 
for service users. 
2. Methadone prescribing is important to ensure (a) that the maximum number of 
users avail of treatment services; (b) the prevention of transmission of the HIV 
virus through infected needles- 
3. That mefchadone is the most appropriate drug for use in a maintenance programme 
for addiction. The Group holds this view 
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so strongly that it would specifically list the following drugs as being unsuitable 
for such programmes: Morphine (MST); 
Dihydrocodeine (DF118); Buphrenorphine (Temgesic); Dipipanone (Diconal), 
Dextromoramide (Palfium). 
The Group is aware that benzodiazepines have potential for abuse and some of them (e.g. 
Flunitrazepam (Rohypnol) and Temazepam (Normison) ) are being injected thus perhaps 
contributing to the transmission of HIV. The Group recognises that benzodiazepines are 
useful in the short term treatment of anxiety and insomnia but stress that prescribing 
doctors should be aware of the abuse associated with them. 
2.2 Methadone, like any other addictive drug, is liable to abuse from a number of 
sources. Therefore, a number of safeguards must be introduced to avoid problems caused 
by double prescribing and its subsequent availability on the black market. Consequently 
it was agreed that control of methadone prescribing was essential. This allows the 
following advantages: - 
(a) The protection of the service and its users 
(b) The protection of the service providers 
(c) An aid to appropriate and responsible prescribing. 
2.3 The Group recognised the validity of Dr. John O’ Connor’s guidelines entitled: 
“Good Clinical Practice in Relation to Methadone Prescribing” as a basis for clinical 
practice. Dr. O’ Connor’s paper is reproduced at Appendix A. 
2.4 In recognition of the complexities of the medical and psycho-social issues involved 
in the treatment of drug use the Group considered that the importance of a 
multidisciplinary approach should be emphasised. The Group considered that a “team 
approach” to the admission of a patient to a methadone prescribing regime was most 
important. This issue is expanded upon later in this Report. 
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3. THE ROLE OF THE GENERAL PRACTITIONER IN 
COMMUNITY METHADONE MAINTENANCE 
PROGRAMMES 
3.1 The Irish College of General Practitioners has stated in its “Policy Statement on 
illicit Drug Use and Problems of Drug Addiction” that the College supports the provision 
of Community Drug Teams and that these Teams should work closely with local general 
practitioners- Doctors who wish to prescribe for patients with addiction problems should 
do so only when satisfied about the adequacy of support from the statutory and voluntary 
services and the availability of proper resources. The Group endorses this view and 
would stress that such prescribing should be within the guidelines issued by the Medical 
Council for the prescribing of controlled drugs. 
(The Medical Council Guidelines are at Appendix B). 
3.2 In practice it is recommended that a person in difficulty with his/her drug use 
should be referred either to the Drug Treatment Centre or to the local health board 
addiction services or to the local Community Drug Team for a full assessment, including 
a psychiatric evaluation. The initial referral could be from the individual’s own doctor, 
public health nurse, drugs out-reach worker, voluntary agency or by self-referral. 
Following assessment it is recommended that the individual should be offered a range of 
options including detoxification, support for a drug-free life, referral to a programme of 
rehabilitation, or a methadone maintenance programme. A key drug worker would be 
identified to work with this person on an on-going basis. After stabilisation as drug-free 
or on a maintenance programme the individual would be introduced to a local doctor who 
had agreed to continue medical care and/or methadone maintenance at a level agreed 
between the doctor, the patient and the addiction services. The Group endorses the role of 
the Community Drug Team and recommends the urgent establishment of other 
Community Drug Teams in areas of greatest need. 
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3.3 There should be regular communication between the doctor and the addiction 
services through the patient’s key drug worker. This should ensure that any problems 
which arise concerning the treatment are quickly identified and dealt with at the most 
appropriate level. This would give support and protection to the patient, the doctor and 
the addiction services- The Group therefore recommends that close cooperation should 
exist between general practitioners and the Community Drug Team/addiction services for 
their area. 
This would also have the effect of establishing the practice of “good care” in the 
prescribing of methadone to opiate-addicted individuals. All doctors would be 
encouraged to accept that this was the preferred treatment option for these problems. 
General practitioners using such a system of care would work in cooperation with their 
local pharmacy colleagues. A nominated pharmacist would dispense for each individual 
drug user on a treatment or maintenance programme and therefore the role of the 
pharmacist will be essential in the on-going development of Community Drug Teams. 
3.4 It is considered that general practitioner sessions would initially take place in the 
Community Based (satellite) Clinics but ultimately it is envisaged that the scheme would 
develop to the point where participating general practitioners would see patients in their 
own surgeries. 
3.5 In providing this service the general practitioner would be strongly supported by 
the appropriate addiction service and by the community care services of the health 
boards. Liaison with acute and chronic hospital services dealing with HIV/AIDS cases 
will need to be fully developed to ensure that the service is as integrated and efficient as 
possible. 
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3.6 The Group recognises that there are general practitioners who are already 
prescribing methadone for patients in the community. As previously stated there are 
considerable difficulties for all concerned if doctors treat patients in isolation. 
Accordingly it is recommended that such doctors should contact the Drug Treatment 
Centre or the health board addiction services in order that their patients can avail of the 
full range of services available and to ensure that their own service is supported and 
protected (i.e. against the possibility of double-prescribing etc.). 
3.7 The Group regards the support of the Drug Treatment Centre and of the health 
board addiction services as being vital to any methadone maintenance programme and 
would therefore recommend in the strongest possible terms that general practitioners 
should not become involved in the provision of such services unless they are provided in 
cooperation with the Centre and /or the addiction services- 
3.8 It is important that all statutory and voluntary bodies working in the area of drug 
use and HIV/AIDS have good communications and work closely together to ensure 
maximum co-operation in order that an optimal level of services are provided to drug 
users and their families-This would serve to help them as individuals and also to prevent 
the spread of HIV infection which is associated with the identified drug use problem 
concentrated in certain areas of Dublin City. 
4. REGISTRATION OF DRUG USERS 
4.1 Registration of drug users 
The Group regarded the issue of the registration of drug users as crucial and were 
cognisant of the need to reach agreement on a formula which would be generally 
acceptable to all the relevant parties. It was agreed that there was widespread resistance 
to the term “register” and 
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accordingly it was decided that the use of the term “register’ was unnecessary and 
unwelcome. 
However, it was agreed that a basic level of control had to be introduced in order: 
(a) to protect the service 
(b) to protect service users 
(c) to protect the service providers 
(d) to avoid double prescribing. 
4.2 Treatment Card 
Having regard to the fact that the Group was established to give effect to proposals that 
services should, as far as possible, be decentralised or community-based it was agreed 
that if a common method of entry to the community-based treatment/addiction services 
could be agreed then the above-mentioned objectives could be achieved- In recognition 
of the fact that there might be a certain hesitancy and anxiety concerning the provision of 
services to drug users at local community level, it was agreed that a “TREATMENT 
CARD” should be introduced to help allay some of these fears. It was decided that a 
treatment card should be provided for each patient who is admitted to the detoxification/ 
maintenance programmes in the community. Following the initial assessment and period 
of stabilisation a patient may be issued with a treatment card and referred to an agreed 
local general practitioner and pharmacist. 
The card would remain the property of the patient at all times. The creation of a treatment 
card for a particular individual would be the outcome of a consultative process 
emphasising the benefits accruing to both the service user and to the service provider. 
One of the obvious benefits would be that it would facilitate integration into the 
community and therefore the provision of such a card for each treatment user would be 
desirable and welcomed by both service users and providers. 
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It is recommended that the following should be included on the treatment card: 
− the name of the patient; 
− the date of birth of the patient; 
− a photograph of the patient; 
− the name of the prescribing doctor. 
It is also recommended that the card should be deposited with the pharmacist or 
appropriate dispensing service by the patient for the duration of his/her treatment 
programme. Acceptance of the card by the pharmacist would not of itself permanently 
bind him/her to provide services for a particular patient. Likewise the patient could 
withdraw the card, for example on termination of his/her treatment programme. In order 
to avoid as far as possible future problems of stolen or mislaid cards and to allay any 
unwarranted concerns regarding confidentiality, it is recommended that each card should 
be valid for a specific period and should carry an expiry date after which a new card 
would be required for continuation of treatment. It is recommended that the cards should 
issue from two sources only: the Drug Treatment Centre, and the health board addiction 
services. 
4.3 treatment list of service users 
In tandem with the proposed treatment card the Group agreed that there was a clear need 
for a list of patients to be maintained centrally not least for purposes of assessing both 
current levels of service provision, and of future trends. Having regard to all the 
circumstances it was agreed that the Drug Treatment Centre, (Trinity Court), would be 
the preferred centre where such a list should be maintained. This would have a number of 
advantages including the most obvious that there would be a central resource which 
would have basic identifying details of all patients seeking treatment throughout the 
country. The proposed list would include details such as the patient’s name and date of 
birth. A patient’s name will be deleted from the list after an appropriate period out of 
treatment, usually one year. 
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It is recommended that for the purposes of co-ordination, each health board providing a 
service such as has been described, should designate a doctor to form a Liaison Group 
with the Clinical Director (.or his deputy) of the Drug Treatment Centre for the purposes 
of ensuring the protection of users/providers, the services and the avoidance of double 
prescribing. 
The Group wishes to place particular emphasis on two issues in this general area:- 
(a) Confidentiality: in this regard it is recommended that because of the nature of the 
information, access to the list should be restricted to doctors providing treatment. 
The maintenance of the list will of course comply with the provisions of the Data 
Protection Act, 1988- In accordance with the provisions of the Act, individuals 
who believe that information is being maintained on computer will be able to apply 
for disclosure of such information in accordance with the usual procedures. 
(b) Liaison and Co-operation: the Group wish to stress the need for a high level of 
liaison and co-ordination between the designated doctors who will have 
responsibility for the maintenance/operation of the list. 
Unlinked statistics will of course be available to the Department of Health, and other 
interested agencies. 
In order to avoid any undue pressure being put on the designated doctors to release 
information, the Group wish to stress that the list is a treatment list, and is not to be 
anything other than such a list. The Group would also wish to emphasise that where 
information is sought regarding a particular individual it should be sought from the initial 
referring doctor. 
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4.4 Dispensing of Methadone 
The Group met with the Irish Pharmaceutical Union (IPU) and the Pharmaceutical 
Society of Ireland (PSI). The Group was most encouraged by the positive response of 
both organisations and their willingness to encourage their members to support the 
proposed initiatives. In practice it was agreed that the community-based pharmacist 
would only dispense methadone to an individual for whom he/she held a treatment card. 
The prescription issued by the doctor would be marked “To be dispensed in _________ 
pharmacy only” which would be an additional safeguard against double prescribing. It 
was agreed that the particular time of delivery and collection of prescriptions by users 
should be agreed locally in order to minimise disruptions to the other activities of the 
pharmacy and to enable the pharmacist to order methadone as it was required rather than 
to force the retention of excessive quantities in stock. The Group were strongly of the 
view that methadone should be dispensed in the same manner as any other similar 
medication. Individuals should not be forced to consume the methadone on the premises. 
4.5 The Group were aware that some drug users may not have access to dispensing 
community pharmacies. In such cases the Group recognises the validity of centralised 
arrangements for the dispensing of methadone - 
5. LICENSING OF GENERAL PRACTITIONERS TO TREAT 
DRUG USERS 
5.1 The Group recognised that this was a very contentious area not least because of the 
difficulty of involving general practitioners in the treatment of drug users. The National 
AIDS Strategy Committee had envisaged that with the provision of adequate facilities 
and safeguards general practitioners would be prepared to take on a comprehensive role 
in the care and treatment of drug users. The Group however, was of the 
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view that licensing would be perceived as very much a negative step and would be 
opposed by the doctors and their representative organisations. It might therefore 
discourage general practitioners from becoming involved in the provision of services. 
5.2 The Group considered that the need for such a form of control would be partially 
obviated by the introduction of the treatment card, as recommended earlier in this Report. 
The introduction of guidelines for good practice will also assist in clearly defining the 
role of the general practitioner in the treatment of drug users. As previously stated in 
Paragraph 3.3 the Group strongly recommend that the prescribing of methadone should 
only take place within the context of a recognised treatment programme with active 
support from the various addiction services, statutory or voluntary, and following the 
guidelines recommended by this Group. 
5.3 The Group did recognise the value of registration of general practitioners as a 
positive measure rather than as a means of imposing restrictions or control. A scheme, 
similar to the combined ante-natal care scheme, was suggested whereby doctors would 
contract to provide care under agreed conditions and for agreed remuneration. Any doctor 
would be eligible to apply to participate in the scheme to the appropriate health board. 
The doctor would keep a list of consultations which would be forwarded for review by 
the appropriate medical officer and passed for payment in due course. 
6. GENERAL ISSUES 
6.1 Co-ordination and co-operation 
The Group are very aware that the recommendations which are contained in this report 
have wide-ranging implications for the delivery of services to drug users. The measures 
which are recommended will 
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change existing services and offer clear guidelines for the delivery of new evolving 
services- The Group fully appreciates the difficulties that could arise in the 
implementation of the recommendations it has made and reiterates the need for the 
closest possible co-operation and liaison in the delivery of the services. 
This Group is confident that the support and co-operation which has been promised by all 
concerned will help to avoid many difficulties which might otherwise occur. However in 
order to ensure that any difficulties which do arise are dealt with as expeditiously as 
possible, in the operation of the protocol and in the implementation of the other 
recommendations contained in this Report, the Group recommends that it should continue 
in existence for an initial phase-in period of twelve months in order to monitor and 
evaluate the proposed arrangements. At the end of this period the situation and necessity 
for such a Group should be reviewed. 
6.2 The following are areas of concern which the Group believe should be monitored 
for an initial period: 
(i) Co-operation and liaison between the various addiction services both 
statutory and voluntary; 
(ii) Co-operation and liaison between the doctors designated by the Drug 
Treatment Centre and the health board addiction services in the operation of 
the treatment list; 
(iii) The avoidance of double-prescribing and inappropriate prescribing by the 
implementation of the Group’s recommendations and in particular the 
operation of the proposed treatment card. 
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7. SUMMARY OF RECOMMENDATIONS 
(i) It is recommended that methadone is the most appropriate drug for use in a 
maintenance programme. 
(ii) It is recommended that doctors who wish to prescribe for patients with 
addiction problems should do so only when satisfied that they are complying 
with the Medical Council guidelines on the prescribing of controlled drugs 
and where there is satisfactory support from the statutory and voluntary 
services. 
(iii) It is recommended that before a person is admitted to a maintenance 
programme he/she should be referred either to the Drug Treatment Centre or 
to the local health board addiction services or to the local Community Drug 
Team for a full assessment including psychiatric evaluation. 
(iv) It is recommended that, following assessment, the individual should be 
offered a range of options including detoxification, support for a drug-free 
life, referral to a programme of rehabilitation, or a methadone maintenance 
programme. 
(v) The group recommends the urgent establishment of other Community Drug 
Teams in areas of greatest need. 
(vi) The Group recommends that close co-operation should exist between 
general practitioners and the Community Drug Team for their area- 
(vii) It is recommended that doctors who are currently treating patients with 
methadone should contact the Drug Treatment Centre or the health board 
addiction services in order that their patients can avail of the full range of 
available services and to ensure that their own service is supported and 
protected. 
(viii) It is recommended that a Treatment Card” should be provided for each 
patient who is admitted to detoxification/maintenance programmes in the 
community and that each card should be valid for a specific period. 
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(ix) It is recommended that the card should issue from two sources only; the 
Drug Treatment Centre and the health board addiction services. 
(x) It is recommended that a list of all patients on methadone therapy should be 
maintained and operated by a Liaison Group consisting of a designated 
doctor from each health board addiction service and the Clinical Director (or 
his Deputy) of the Drug Treatment Centre. 
(xi) It is recommended that because of the confidential nature of the information, 
access to the list should be restricted to doctors providing treatment and 
comply with the guidelines set out by the Medical Council and the Data 
Protection Act. 
(xii) It is recommended that community-based pharmacists should only dispense 
methadone for individuals for whom they hold a treatment card and that 
methadone should be dispensed in the same manner as any other similar 
medication. 
(xiii) It is strongly recommended that the prescribing of methadone should only 
take place within the context of a recognised treatment/maintenance 
programme encompassing support from the various addiction services, 
statutory or voluntary, and following the guidelines recommended by this 
Group. 
(xiv) It is recommended that the Group should continue to monitor and evaluate 
the proposed arrangements and their operation for an initial phase-in period 
until the measures recommended in this report are operating satisfactorily. 
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APPENDIX A 
GOOD CLINICAL PRACTICE IN RELATION TO 
METHADONE PRESCRIBING 
Dr. John J. O’ Connor, Consultant Psychiatrist/Clinical Director Drug Treatment 
Centre, Trinity Court. 
January 1993 
Methadone has a similar pharmacological spectrum to heroin. It is usually taken orally 
and in view of its longer half-life can be given on a once daily dosage thus ruling out the 
need to inject drugs and the drug seeking behaviour, that ensues. 
MEDICAL 
Medical examination should include assessment of Respiratory, Cardiac, G.I.T. and 
C.N.S- systems. The medical evaluation should also include examination of a patient’s 
upper and lower limbs and groin i.e. injection sites. 
PSYCHIATRIC 
Psychiatric evaluation includes examination for any co-existing personality disorder, mild 
mental handicap, psychotic or depressive illness. 
SOCIAL 
Social history should be obtained at this stage and where possible a collateral history 
from a relative or concerned person. 
URINALYSIS 
Obtaining urine should be supervised and analysis is carried out for the following 
reasons. 
(a) Urine checked for particular drugs of abuse, and that the results are consistent with 
the patients history. 
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(b) To ensure that the patient is not already receiving Methadone elsewhere. 
TREATMENT PLAN 
Methadone Detoxification/Maintenance 
The decision as to whether a patient should be given a detoxification or maintenance is 
based on a number of factors. It is good clinical practice to encourage a patient on first 
presentation to become drug free and avail of the opportunity for an independent lifestyle. 
Maintenance is usually decided as the best option if; - 
(a) Previous failed detoxifications 
(b) Inability to remain drug free 
(c) Length of time abusing drugs 
(d) Physical ill health: medical problems including HIV 
(e) In the case of women - pregnancy 
For a withdrawal regime a starting dose on 30-40 mgs ought to be sufficient, and 
thereafter reducing by 5 mgs every three days. It should be remembered that 
psychological factors play a large part in the manifestations of the withdrawal syndrome 
and a supportive reassuring approach can often greatly reduce the severity of the 
symptoms experienced. 
Many patients are not as physically dependent on opiates as they assume, particularly if 
they have been using heroin which can be very impure. Dublin street heroin is on average 
only 10 - 15 % pure. It is better to prescribe a lower dose and then increase it if the 
person is experiencing withdrawal symptoms than to prescribe a level that will induce 
intoxication and increase physical tolerance. Methadone should initially be administered 
on a daily basis and evidence of improvement in drug taking behaviour should include 
reference to regular supervised urinalysis. A few days supply of Methadone should only 
be given to those 
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who cope well with daily administration. 
A patient presenting in obvious withdrawals can either be given symptomatic relief with 
melleril, ponstan and lomotil or a low dose of Methadone followed by referral the next 
day to a treatment centre. 
ABUSE POTENTIAL 
The potential for abuse of Methadone should not be forgotten. Already there is a thriving 
black market for Methadone on the street. To combat this and the problem of double 
scripting it is essential that a central register for Methadone prescribing be instituted 
immediately. 
Finally, Methadone should not be seen as an easy solution to a complex problem. 
Methadone should always be regarded only as a adjunct to treatment and not treatment 
per se. 
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Appendix B 
RECOMMENDATIONS 
OF THE MEDICAL COUNCIL FOR THE 
PRESCRIBING OF CONTROLLED DRUGS UNDER 
THE MISUSE OF DRUGS ACTS, 1977 AND 1984 
1 Practitioners must ensure that all prescriptions for controlled drugs are 
written in the format specified in the Misuse of Drugs Regulations. 
Incorrectly written prescriptions cannot lawfully be dispensed by 
pharmacists. 
2 Practitioners and pharmacists in each area should reach an understanding 
about prescribing and dispensing controlled drugs. On the basis of such 
understanding pharmacists should be in a position to meet the legitimate 
needs of patients promptly. 
3 Practitioners should not treat patients from outside their practice areas for 
addiction problems by prescribing controlled drugs. Practitioners are advised 
to refer such patients to recognised drug treatment centres. 
4 Patients should be discouraged from moving from pharmacy to pharmacy 
with prescriptions for controlled drugs. 
5 A practitioner who has patients referred from a drug treatment centre for 
continuation of treatment, with the patient’s consent, should discuss the 
likely treatment regimen with the patient’s pharmacist. 
6 Doctors should report problems in the prescribing of controlled drugs to the 
Medical Council. 
Issued on behalf of the Medical Council and the Pharmaceutical Society of Ireland, January 1987. 
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Misuse of Drugs Acts, 1977 and 1984 
PRESCRIPTION WRITING REQUIREMENTS 
It is unlawful for a practitioner to issue, or for a pharmacist to dispense, a prescription 
for a Schedule 2 or 3 drug unless it complies with the following requirements: 
The prescription must: 
A be in ink or otherwise indelible and be signed by the practitioner with his/her 
usual signature and dated by him/her. 
B clearly indicate the name of the practitioner issuing it and, except in the case 
of a health prescription (GMS), specify his/her address 
C specify (in the prescriber’s handwriting) the name including given name, and 
address of the person for whose treatment it is issued. 
D state that the person issuing it, is a registered medical practitioner, and a 
telephone number at which the practitioner may be contacted. 
E specify (in the prescriber’s handwriting) (i) the dose to be taken, (ii) the form 
in the case of preparations, (iii) the strength (when appropriate) and (iv) in 
both words and figures, either the total quantity of the drug or preparation or 
the number of dosage units to be supplied. 
F in the case of a prescription for a total quantity intended to be dispensed by 
instalments, specify the amount of the instalments and the intervals at which 
the instalments may be dispensed. 
Notes: 1. The practitioner must also be satisfied as to the identity of the person for whose treatment 
the prescription is being issued. The pharmacist must also be satisfied in this regard. 
2. Prescriptions for controlled drugs may not be repeated. 
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A LIST OF THE MOST COMMON CONTROLLED DRUGS 
SCHEDULE 2 
Class of Controlled Drug Proprietary Products 
Altentanyl Rapifen 
Amphetamine  
Buprenorphine Temgesic 
Cocaine 
Codeine 
Dextromoramide Palfium 
Dihydrocodeine DF 118, DHC Continus 
Dipipanone Diconal 
Fentanyl Sublimaze, Durogesic 
Hydrocodone 
Hydromorphone Dilaudid, Palladone, Palladone SR 
Levactylmethadol Orlaam 
Levorphanol Dromoran 
Medicinal Opium (which includes Omnopon 
Papaveretum and Opium Tincture BP) 
Methadone Physeptone 
Methylphenidate Ritain 
Morphine Cyclimorph. Morstet SR. MSTContinus, MXL, 
Sevredol, Oramorph Concentrate, Qramorph UDV 
Pethidine 
Pholcodine 
Phenoperidine Operidine 
Quinalbarbitone Seconal, Tuinal 
Sufentanil Sufenta 
SCHEDULE 3 
Amylobarbitone Sodium Amytal 
Diethylpropion 
Flunitrazepam Rohypnol 
Mazindol Teronac 
Meprobamate Equagesic, Equanil 
Pentazocine Fortral, Fortagesic 
Phenobarbitone Gardenal Sodium 200mg 
Phentermine Duromine, lonamin 
Temazepam Euhypnos, Normison, Nortem, Tenox 
NOTE: The stricter rules for writing prescriptions do not apply to the following: 
(i) preparations containing not more than 100mg per dosage unit of metnylphenobarbitone or phenobarbitone (each 
calculated as base). 
(ii) preparations containing not more than 0.1% of cocaine or 0.2% of morphine (each calculated as base). 
(iii) preparations (other than injections) containing not more than 100mg per dosage unit of codeine or pholcodine 
(each calculated as base) or in undivided preparations not more than 2.5% of either drug. 
(iv) preparations (other than injections) containing not more than 10mg per dosage unit of dihydrocodeine (calculated 
as base) or in undivided preparations not more than 1.5%. 
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APPENDIX 2 
RECOMMENDATION OF THE PHARMACEUTICAL 
SOCIETY OF IRELAND POLICY ON DRUG ABUSE 
October 1996 
12. Summary of Recommendations 
The following are the main recommendations of the Pharmaceutical Society of Ireland on 
how best the problem of drug abuse may be addressed and how the role of the pharmacist 
may be employed in this. These are taken from the main body of the policy document and 
each recommendation is followed by a reference to its location in the document. 
12.1 Role of the pharmacist 
12.1.1 Sale of medicines 
All medicines should be sold from pharmacies and pack size, supplies and 
usage should be limited to safe, effective levels. (5.5.1) 
12.1.2 Counselling on medicines usage 
All medicines should be issued to the public with counselling and the 
pharmacist should be available for consultation with the patient. (5.5.2) 
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12.1.3 Licensing of pharmacies 
A licensing system should be introduced for pharmacies to give an even 
geographical distribution, highest professional standards and the 
maximisation of professional services offered. (5.5.3) 
12.1.4 Role of the pharmacist 
The role of the pharmacist within the community is a most valuable asset 
which must be utilised to its full potential if the problem of drug abuse is to 
be tackled effectively. (5.5.4). 
12.1.5 Training and service co-ordinator 
One of more full-time co-ordinators should be appointed to oversee all 
aspects of pharmacy involvement in the drug abuse prevention and 
treatment services. (6.5) 
12.1.6 Identification of samples 
Requests for identification of suspicious samples from members of the 
public should be facilitated insofar as possible. (8.3) 
12.1.7 Health promotion 
A health promotion section for the display of promotional and educational 
materials should be available to the public in all pharmacies. (8.7.3) 
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12.2 Education issues 
12.2.1 Surveys on drug use among adolescents 
Biennial surveys to be carried out to monitor the extent of drug use among 
adolescents at school and young people outside the school system- (4.2.4.2) 
12.2.2 Information on drugs 
Pharmacists form a ready-made community network providing easy access 
to drug information for the general public and as such are ideally placed to 
play a major role in drug education. (6.6.1) 
12.2.3 Survey of training needs 
In order to ascertain what level and type of training is required so as to 
enable pharmacists to become effective community educators, it might be 
necessary to undertake a survey of pharmacists on this matter. (6-2.4) 
12.2.4 Training programme for pharmacists 
A training programme for pharmacists who wish to become involved in drug 
education should be organised. This would provide pharmacists with the 
necessary presentation and attitude insight skills to enable them to 
successfully impart their knowledge to others. A suitable support package 
should be developed for appropriately trained pharmacists. (6.3). 
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12.2.5 Liaison with other groups 
Liaison with the Health Promotion Unit of the Department of Health should 
be encouraged to enable pharmacists to avail of the excellent range of 
promotional and educational materials provided by the Health Promotion 
Unit. (6.4) 
12.2.6 Sharing presentations 
Pharmacists should not share presentations with speakers who also discuss 
the effects of drugs unless these speakers are qualified to do so. (6.6.7) 
12.2.7 Information on drug use statistics 
Liaison with the Garda Siochana should be organised to enable pharmacists 
to avail of up-to-date statistics on drug use in local areas. (6.6-6) 
12.2.8 Substance Abuse Prevention Programme 
The efforts of the Departments of Education and Health in organising the 
Substance Abuse Prevention Programme for secondary schools and the 
dedication of the hundreds of teachers who participated in it are to be 
applauded. A similar programme for primary school children, their parents 
and teachers would be another important step in demand reduction. (6.4.3) 
12.2.9 Participation in Substance Abuse Prevention Programme 
Pharmacists throughout the country should contribute to the successful 
implementation of these programmes by 
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building on the existing technical support given by individuals to the project 
development. (6.6.8) 
12.2.10 Heroin smoking 
An education campaign on the dangers of heroin smoking to be initiated as a 
matter of urgency. (4.2-4.5) 
12.3 Maintenance and care of addiction 
12.3.1 Participation in methadone dispensing 
All pharmacists should be encouraged to dispense methadone for patients in 
accordance with the guidelines for dispensing of methadone detailed in the 
report. (7.1.2 and 7.1.3) 
12.3.2 Clinical information 
Information on all aspects of methadone programmes should be made 
available to pharmacists to enable them to more fully understand the 
management of opiate addiction. (7.1.1.4) 
12.3.3 Methadone formulations 
Methadone Img/lml is the preferred strength for use in treatment 
programmes. (7.1.1.4) 
12.3.4 Alternative treatments 
It is hoped that non-opioid alternatives to methadone for the 
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management of addiction will be considered in the future. (7.1) 
12.3.5 Pharmacist/patient contract 
Any pharmacist dispensing methadone for a patient should ensure that both 
they themselves and the patient have signed a pharmacist/patient contract. 
(7.1.5) 
12.3.6 Needle and syringe exchange 
The principle of needle and syringe exchange is recognised as a proactive 
approach to health promotion and a properly co-ordinated, funded and 
supervised national needle and syringe exchange network with clear policies 
on the primary practice issues of supply, receipt, safe custody and disposal 
should be established. (7.2) 
12.3.7 Local drug services 
Pharmacists should draw up a list of drug treatment and counselling services 
in their local area, to be used in conjunction with presently available 
directories to assist people who approach them for advice on these services. 
(8-2) 
12.3.8 Counselling services 
The level of services, both general and specialised, for drug abuse 
counselling should be greatly increased. (8.4) 
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12.3.9 Methadone treatment charges 
Methadone should be supplied free of charge to all persons undergoing a 
recognised drug treatment programme. (7.3.1.1) 
12.4 Legal issues 
12.4.1 Solvents 
Self-service sales of solvents to be banned. (4.2.4.1) 
12.4.2 New schedule to the Misuse of Drugs Regulations 
Certain drugs which are used in the treatment of drug addiction should be 
entered in a new schedule to the Misuse of Drugs Regulations, 1988-1993, 
to be called Schedule 6. (9.2) 
12.4.3 Powers of the Pharmaceutical Society of Ireland 
The Misuse of Drugs Regulations, 1988 should be amended to give powers 
of inspection and entitlement to information in respect of controlled drugs in 
community pharmacies, hospitals and pharmaceutical wholesalers to the 
Pharmaceutical Society. (9.3) 
12.4.4 Dispensing of controlled drugs 
Dispensing of controlled drugs should take place in a community pharmacy, 
a hospital pharmacy department or an official health board drug treatment 
service. (9.4) 
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Dispensing should be carried out by a pharmacist, and where this is not 
possible, the dispensary service should be overseen by a co-ordinating 
pharmacist. (9.4) 
12.4.5 Treatment referral 
Drug addicts convicted of minor drugs related offenses should have the 
option, when this is considered suitable, of taking a place on a recognised 
drug treatment service instead of a custodial sentence. (9-5) 
12.4.6 Drug-free units in prisons 
Insofar as it is practically possible, each prison in the State should have a 
specially designated drug-free unit. (9.6) 
12.4.7 Government initiatives 
While the present government initiatives on tackling drug abuse are 
welcomed, it is regrettable that very little cognisance is taken of the possible 
contribution which pharmacists could make to a resolution of the problem- 
(9.7) 
12.4.8 Present legal classifications 
No change should be made to the legal status of any substance listed in 
Schedule 1 to the Misuse of Drugs Regulations, 1988-1993. (9.8) 
12.4.9 Elimination of illicit drug supply 
Further emphasis to be placed on elimination of the supply 
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side of the drugs problem at all levels, retail, wholesale and import. (4.2.4.3) 
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APPENDIX 3 
RECOMMENDATIONS OF THE IRISH COLLEGE OF 
GENERAL PRACTITIONERS’ TASK GROUP ON DRUG 
MISUSE 
May, 1997 
Some recommendations are followed by a reference to their locations in the ICGP 
report. 
SUMMARY OF RECOMMENDATIONS 
1. General Practice has an important contribution to make in the management and 
prevention of drug misuse, together with other medical, social, and political 
agencies. (Section 1). 
2. The causes of drug misuse have major social, economic, and educational roots, as 
well as medical, and proposed solutions to the problem must address all of these 
factors. (Section 2). 
3. Alcohol and benzodiazepines (whether prescribed or obtained illegally) are the 
most common causes of drug misuse in Ireland, but this document deliberately 
confines itself to the problem of opiate addiction. 
4. The Task Group recommends a model of care for opiate addicts based in general 
practice, with GPs providing methadone maintenance (Level 1) where appropriate, 
or methadone initiation as well as maintenance (Level 2) where appropriate. 
(Section 4). 
5. There must be an adequate number of GP facilitators appointed, who have the 
necessary expertise and commitment to enroll, support, liaise with, and advise 
GPs. (Section 4). 
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6. There must be a confidential national treatment list on which all patients receiving 
methadone will be entered-(Section 4). 
7. All patients receiving methadone must have an individualised treatment card, 
which is supplied to and kept at their pharmacy. (Section 4). 
8. Methadone treatment, including prescriptions, should be free of charge to opiate 
addicts. (Section 4). 
9. Prescribing of methadone should be budget neutral to GPs. (Section 4). 
10. Methadone must be dispensed at a local pharmacy, and where indicated in daily 
doses, preferably with supervised ingestion on the premises. (Section 4). 
11. There must be local access to the fall range of services needed to assess, treat, and 
follow-up opiate dependent patients. (Section 4). 
12. There must be a flexible, quick, and easily accessible referral and re-referral 
system available to GPs-(Section 4). 
13. There must be suitable training and education for participating doctors, including 
assessment for certification and re-certification. (Section 4). 
14. There must be adequate, negotiated, and agreed payment for certified participating 
doctors. (Section 4). 
15. The number of addicts being treated by any single GP should not 
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exceed 10-15 for Level 1 doctors, or 30-35 for Level 2 doctors. (Section 4). 
16. The criteria for patients suitable for treatment in general practice by Level 1 and by 
Level 2 GPs are proposed. (Section 5). 
17. A joint ICGP/Health Board Review Group is proposed, which would have 
responsibility for overseeing and approving education and assessment, as well as 
policy development. (Appendix C). 
18. The field of drug misuse is dynamic and rapidly changing, and ICGP policy in this 
area will need to be kept under continuous review. 
19. The ICGP expects that this policy document, together with the Fact Files, will 
encourage its members to take part in the medical management of drug misusers at 
all levels, and to participate in the Methadone Protocol where clinically 
appropriate. 
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